{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"7"}]}],"title":"Abdominal pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"16"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"15"}]}],"title":"Hypertension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"}]}],"title":"Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"}]}],"title":"Rash maculo-papular"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"}]}],"title":"Small Intestinal Obstruction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}]}],"title":"Vomiting"}],"denoms":[{"counts":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"127"}],"units":"Participants"}],"description":"Number of treated patients with Adverse Events (grade 3 or higher) observed while receiving randomized therapy. Excludes AEs observed among control patients treated with trametinib after crossover.Participants were analyzed based on their group of assignment. Patients on Arm A who progressed were permitted to receive Arm B treatment. Study time for Arm A patients who crossed over was not included in the AE endpoint definition.","groups":[{"description":"Investigators choice of Letrozole 2.5 mg po qd continuously, tamoxifen 20mg po bid continuously, paclitaxel 80mg/m2 IV over 1 hr on day 1q 7d, 3 wks on, 1 wk off, Pegylated Liposomal Doxorubicin 40 or 50mg/m2 IV over 1 hr on day 1 q. 28d, Topotecan 4.0mg/m2 over 30 min on day 1,8 and 15 of a 28 day cycle. For each arm, 1 cycle - 28 days","id":"OG000","title":"Arm A - Control Arm"},{"description":"Trametinib 2 mg po daily continuous treatment, For each arm, 1 cycle = 28 days","id":"OG001","title":"Arm B - Experimental Arm"}],"paramType":"NUMBER","populationDescription":"Treated with randomized therapy","reportingStatus":"POSTED","timeFrame":"During treatment period and up to 100 days after stopping the study treatment","title":"Incidence of Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"participants"}